

## Gilead Sciences Croatia EFPIA Report 2021

Disclosure date: 30/06/2022

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country local identifier (optional)	Donations to HCOs	Contribution to costs of Events (Art. 21.1.A.(ii) and 21.1.B.(i))			Fee for services (Art. 21.1.A.(iii) and 21.1.B.(ii))		TOTAL Optional	
	(Art. 19.1.)	(Art. 20.6)	(Art. 20.6. related to Art. 21.)	(Art. 20.6.)	(Art. 20.6.)	(Art. 21.1.A.(i))	Sponsorship agreements with HCOs/third parties appointed by HCOs to manage Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for services contract		
INDIVIDUAL NAMED DISCLOSURE – one line per HCP (i.e. all Transfers of Value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCPs													
	OTHER, NOT INDICATED ABOVE: where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to ToV to such Recipient – Art. 21.2.1.						N/A	N/A	74,764.31 kn		37,350.00 kn		112,114.31 kn
	Number of Recipients (named list, where appropriate) – Art. 21.2.1.						N/A	N/A	23		2		25
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed – Art. 21.2.1.						N/A	N/A	100%		100%		N/A	
INDIVIDUAL NAMED DISCLOSURE – one line per HCO (i.e. all Transfers of Value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only as appropriate)													
HCOs													
	OTHER, NOT INDICATED ABOVE: where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to ToV to such Recipients – Art. 21.2.1.												
	Number of Recipients (named list, where appropriate) – Art. 21.2.1.												
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed – Art. 21.2.1.													
AGGREGATE DISCLOSURE													
Research & Development	Transfers of Value for Research & Development under Art. 21.2.2.										224,937.25 kn	112,114.31 kn	